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Abstract
While static microsimulation models of the tax-transfer system are now available throughout
the developed world, health microsimulation models are much rarer. This is, at least in part,
due to the difficulties in creating adequate base micro-datasets upon which the
microsimulation models can be constructed. In sharp contrast to tax-transfer modelling, no
readily available microdata set typically contains all the health status, health service usage
and socio-demographic information required for a sophisticated health microsimulation
model. This paper describes three new techniques developed to overcome survey data
limitations when constructing 'MediSim', a microsimulation model of the Australian
Pharmaceutical Benefits Scheme. Comparable statistical matching and data imputation
techniques may be of relevance to other modellers, as they attempt to overcome similar data
deficiencies. The 2001 national health survey (NHS) was the main data source for MediSim.
However, the NHS has a number of limitations for use in a microsimulation model. To
compensate for this, we statistically matched the NHS with another national survey to create
synthetic families and get a complete record for every individual within each family. Further,
we used complementary datasets to impute short term health conditions and prescribed drug
usage for both short- and long-term health conditions. The application of statistical
matching methods and use of complementary data sets significantly improved the usefulness
of the NHS as a base dataset for MediSim.
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 Introduction
1.1
During the past decade static microsimulation models of the income tax and cash transfer
systems of developed countries have become very widespread (Harding and Gupta 2007, p.
8). For example, within Europe, EUROMOD has allowed the 15 original member countries of
the European Commission to easily examine changes in tax-transfer systems in a comparable
way and is now being extended to embrace the 10 new EC countries as well as indirect taxes
and non-cash benefits (Sutherland 2007). Within Australia, the publicly available STINMOD
model has been available for the past decade (Percival et al 2007) and Canada, the US,
Norway and Spain also have such static microsimulation models (for overviews see Gupta and
Harding 2007, pp.29-32). These models have meant that policy makers within the tax-
transfer field within these countries have been able to readily estimate the detailed
distributional and revenue consequences of a vast range of possible policy changes.
1.2
This stands in stark contrast to the paucity of distributional information available to health
policy makers in most countries. While in many countries outlays on government provided or
subsidized health services and products can approach or exceed outlays on cash transfers —
and despite on-going concerns about possible social gradients in health and in health service
usage (Walker et al 2006, AIHW 2006, Thurecht et al 2005, Turell and Mathers 2000, Walker
and Abello 2000) — health policy makers are generally not able to draw upon sophisticated
microsimulation models to help them assess the distributional consequences of policy
changes that they are contemplating.
1.3
For example, across much of the industrialized world, the proportion of total government
health outlays devoted to pharmaceutical drugs has been rising more rapidly than other
components of health outlays (OECD Health Data 2005 and 2007, Medical News Today 2006).
In Australia, for example, outlays on subsidized pharmaceuticals peaked at 14 per cent of
total health outlays in 2002, up from only 8 percent fifteen years ago (OECD Health Data
2007). In several countries, including Canada and Australia, such rapid growth has prompted
concern about the sustainability of the programs (Paris and Docteur 2006, Moise and Docteur
2007, Maynard and Bloor 2003, OECD Observer 2004).30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
Page 2 of 31 http://jasss.soc.surrey.ac.uk/11/3/2.html
1.4
Access to appropriately subsidized medicines is clearly a vital contributor to the well-being of
families and individuals, particularly low income families. Yet only Canada and Australia
appear to have developed the requisite microsimulation modelling infrastructure for assessing
the current and future impact of possible policy reforms in this area (Gupta, 2007, Nguyen
and Gupta 2007, Abello and Brown 2007).
1.5
Arguably, part of the reason why microsimulation models of the health sector have been
slower to develop is the greater difficulties encountered when attempting to simulate health
status and health service usage, relative to simulating cash transfer receipt or the payment of
income taxes. While most countries now possess the detailed and publicly available microdata
about household incomes and demographic characteristics that will permit ready replication
of the rules of the tax-transfer system, household microdata about health status, health
service usage and socio-demographic characteristics are often not as freely available and/or
less comprehensive than required.
1.6
This article provides an insight into some of the major challenges that faced us as we
attempted to construct a microsimulation model of pharmaceutical drug usage and cost for
Australians. The construction of an adequate base microdata set, with the requisite
information to allow simulation of drug usage and the family-based 'safety net' (designed to
protect families with unusually high drug expenditures), necessitated unusually complex
microsimulation techniques. As Nguyen and Gupta note about their broadly comparable
Pharmasim microsimulation model for Canada, the creation of such a broad data set 'is one of
the biggest challenges in the process due to non-availability of existing data sources that
simultaneously contain all of the required information' (2007). This article is thus designed to
provide insight to other modellers about possible methods for augmenting microdata sets
that do not contain all the variables required for microsimulation of a particular aspect of
social or tax policy.
1.7
Three particular methodological challenges are canvassed in this article. The first was how to
match the individuals recorded into the Australian National Health Survey microdata into
synthetic families (required for modelling the family 'safety net'). The second was how to add
short-term health conditions onto the National Health Survey, which only contained
information about long-term health conditions. The third was how to impute detailed drug
usage patterns for the individuals captured in the National Health Survey, as it only covered
prescribed medicines for national health priority areas that were specified as long-term by
the respondent — a subset of total pharmaceutical drug usage.
Overview of the Australian PBS
1.8
The Australian Commonwealth Government's Pharmaceutical Benefits Scheme (PBS) aims to
provide Australians with timely, reliable and affordable access to necessary and cost-effective
prescription medicines.
1.9
Patients are required to make a contribution to the cost of prescribed medicines listed on the
PBS. Individuals and families eligible for certain federal government pensions and allowances
(e.g. age pension, unemployment benefit, disability pension) are able to access PBS medicines
at concessional rates. These persons are known as concession cardholders. The PBS also has
'safety net' arrangements to protect individuals and families from large overall expenses for
PBS-listed medicines. The levels of patient copayments and the PBS safety net arrangements
are referred to as the PBS policy settings. Patient copayments and safety net thresholds (SNTs)
are revised annually in line with movements in the consumer price index (CPI) from 1 January
each year.
1.10
The majority of prescribed drug sales in Australia are covered by the scheme and, on average,
the government subsidises patients to the extent of 84 percent of PBS drug costs. Currently
nearly 80 percent of total government subsidies through the PBS accrue to concessional
patients (those with the Pensioner Concession Card, the Commonwealth Seniors Health Card
and the Health Care Card) and 20 percent to general patients.
1.11
Finding ways of curbing government expenditure on the PBS, while maintaining social equity
and access to 'essential' medicines, is a continuing concern within federal health and financial
public policy circles. Since the early 1990s government expenditure on the PBS has grown at
more than 10 percent a year — well above the growth in the health budget (6 percent) or the
economy (4 percent in terms of gross domestic product). However, over the next couple of
years, rates of growth in PBS expenditure are likely to be below the long run average growth
of the PBS. The Australian Commonwealth Treasury is forecasting PBS expenditure to grow
over the coming three years at an average of 5.4 percent per annum in real terms, compared
to 3.3 percent for the total health budget (Commonwealth Treasury 2005). Government's
share of the costs of the PBS has steadily increased over time as PBS settings — patient
copayments and safety net thresholds — which largely determine patient contributions, have
increased in general only in line with inflation. In 2004-05, total PBS scripts reached 169
million and cost the government $5.4 billion. PBS-listed scripts priced below copayment
reached 30 million (figure 1).30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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Figure 1. Volume of PBS-listed scripts, 1995-96 to 2005-06. 
Data sources: Medicare Australia website; Drug Utilisation Sub-Committee (DUSC) Drug
Utilisation Database, Pharmaceutical Benefits Branch, Commonwealth Department of Health
and Ageing.
Microsimulation Modelling Using MediSim
1.12
Microsimulation is a means of modelling real life events by simulating the actions of the
individual units that make up the system where the events occur (Brown and Harding 2005).
Microsimulation models are based on microdata i.e. "low-level" population data — typically
the records of individuals from either a national sample survey conducted by a national
Bureau of Statistics or large administrative databases. In other words, microsimulation models
begin with a dataset that contains detailed information about the characteristics of each
person and family (income unit) or household within a sample survey or an administrative
database (Brown and Harding 2002).
1.13
Microsimulation techniques bring a range of benefits to this type of modelling exercise: the
models' databases can mirror the heterogeneity in the population as revealed in the large
household surveys; they can replicate the complexity of the policy structures, transfers, and
settings under investigation; and they can be used to forecast the outcomes of policy changes
and 'what if' scenarios (i.e. the counterfactual where the results describe what, under specified
conditions, may happen to particular individuals and groups). With the model being based on
unit records, it is possible to examine the effects of policy changes for narrowly defined
groups of individuals or demographic groups — and the models provide the ability to change
a greater variety of parameters independently and therefore have the capacity to provide
considerably more accurate estimates and detailed projections of the distributional effects of
changes (Creedy 2001; Brown and Harding 2002; Brown and Harding 2005).
1.14
NATSEM models the Australian PBS using the microsimulation model MediSim. MediSim
simulates the current and future use and costs of PBS medicines under existing and different
policy settings (see, for example, Walker 2000, Walker et al 2000, Harding et al 2004, Brown
et al 2005a and Brown et al 2005b). It also estimates the distributional effects of policy
changes on Australian families. By altering the medicines included in the model, their
assigned prices and script volumes, MediSim is capable of simulating the impact of: inclusion
of new drugs on to the PBS list; restriction on the drugs listed on the scheme or on the
pricing of drugs; increased restrictions on drugs by indication; increased use of generics at
more competitive prices; or an increased emphasis on the quality use of medicines as
reflected in changes in doctor prescribing behaviour; as well as changes to copayment and
safety net arrangements.
1.15
The model could be used to provide answers to relatively simple issues such as the impact of
expected changes in PBS subsidised drug prices and scripts over the next 5 to 10 years on
government PBS outlays, or patient out-of-pocket expenditures and related revenues to
industry. It can also be used to assess more complex matters such as the likely impact of, for
example, the introduction of new PBS listed drugs, the effects of demographic and socio-
economic changes upon outlays, or the distributional and revenue impacts of changing the
rules of the PBS (such as the introduction of differential copayment levels as operate in many
European countries).
Choice of Base Data
1.16
In 2003, NATSEM obtained joint industry and national competitive research funding to extend
the capability of the model to include health outcomes and the evaluation not only of the
costs but also the benefits arising from the use of medicines. A necessary step to modelling30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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both the costs and benefits of these medicines is the inclusion of diseases and health
conditions in the model's base file.
1.17
The model's original base, STINMOD/01a[1], was created from the Household Expenditure
Survey (HES). It was thought initially that the best way to add diseases into the model's dataset
was to replace the model's original base file (which in this paper we interchangeably refer to
as "HES"), with either the 2001 or 1995 National Health Survey (NHS). The 1995 NHS is the
best source of complete (although not up-to-date) information on illnesses and medicine
usage. The 2001 NHS, on the other hand, contains the latest person-level information in
Australia on long-term health conditions, drug usage for national health priority
conditions[2], and health risk factors. However, the latter has a number of limitations as the
base data for a microsimulation model following changes in survey design relative to previous
surveys.
1.18
The 2001 NHS contains only limited information on prescribed medicine use (e.g. only usage
related to priority diseases has been collected), and short-term health conditions (apart from
the priority areas, the survey collected specific information on the health condition only of
persons with long term conditions). Data on drug usage and the health condition/s for which
the medicines are being taken, are essential in a model concerning usage of prescribed
medicines. While the national priority areas, that are included in the survey, constitute a large
share of the PBS (55% of scripts and 64% of costs), the residual that constitutes non-priority
areas is still large and should be included in the model. Another major shortcoming of the
2001 NHS in regard to the PBS concerns the coverage of the survey. Unlike previous national
health surveys, the 2001 survey did not obtain information on all persons in the household,
so the Australian Bureau of Statistics (ABS) recommends that analysis of the 2001 file be done
at the person level only (ABS 2003a). As the PBS annual safety net operates at the income
unit[3] level, complete information on all family or income unit members (particularly on drug
usage) is needed to adequately model this critical component of the PBS system.
1.19
Given the lack of currency of the 1995 health survey, the best option was to build the new
model upon a dataset based on the 2001 NHS but modified such that there was complete
information on each member of a family, and with additional information on short-term
health conditions and drug usage. This was achieved by statistically matching the 2001 NHS
to a person-level dataset derived from NATSEM's STINMOD/01a[4], and augmenting the
resulting base file with information from the 1995 NHS on short-term health conditions and
drug usage.
1.20
The next sections describe the methodology used for statistical matching (Section 2),
imputation of short-term conditions (Section 3) and imputation of prescribed drug usage
(Section 4). The paper concludes with a discussion of the outcomes of the imputations, and
suggests possible future improvements and extensions of the model.
 Statistical Matching
2.1
Statistical matching is a procedure used to link two files or datasets where each record from
one of the files is matched with a record from the second file that generally does not
represent the same unit, but does represent a similar unit. It is a method to bring together
microdata that are not available from a single data source[5]. Since the records to be matched
in this exercise involve sample surveys (rather than administrative data or a census), and
considering the incomplete coverage of families in the 2001 NHS, the matching of records
involves finding the closest statistical match rather than actual matching of data records of
the same persons.
The Data to be Matched
2.2
The HES contains around 18,000 person records and contains detailed income and
expenditure information. Each record has a unique identifier at the household, family, income
unit and person level. This hierarchy allows identification of persons to their correct income
unit, family or household. Having this detail allows the proper modelling of the PBS safety net
as expenditures on PBS drugs can be summed for each income unit.
2.3
The NHS contains around 27,000 person records. The NHS records have detailed information
relating to the health of each person. To link records in both data sets, we need variables that
are common to both data sets and strongly relate to the modelling area, in this case health.




Differences in sample size among the different surveys should not be an issue as weighted
duplications of records may be created so that the sample sizes in both datasets are equal
(Taylor, Gomulka and Sutherland 2000). The main difficulty likely to be encountered is the
choice of weights in the merged file. The weights in either the NHS or HES could be selected
— but the risk is that the statistical distribution and parameters of the variables merged from
the other survey will not be maintained. If constrained statistical matching is used, then the
goal is to try to maintain the marginal distributions of the non-matched variables by
minimising the difference in the weights of the records in the merged file to those of the two30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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original surveys (Cohen 1991).
2.5
Prior to the actual matching, modifications to each dataset were made to make the matching
variables from each dataset consistent. In the HES, we created separate data records for
children, imputed concession card status (used to identify individuals and families who are
eligible to access medicines at concessional rates) and estimated equivalent income deciles
consistent with the 2001 NHS definition. In the NHS, we imputed a value for equivalent
income decile when the response was 'not stated', and used self-assessed health status as a
proxy indicator for income unit expenditure on prescriptions.
2.6
The details regarding modifications made to the data, details of the statistical matching
procedure, the conditional independence assumption, definitions and differences between
constrained and unconstrained matching, among other issues, are described in Technical
Working Group ABS-NATSEM Collaboration on Statistical Matching (2004).
Statistical Matching Methodology
2.7
A two-step approach is used to statistically match the NHS and HES. First, person records are
grouped, mainly by their income unit characteristics, into homogeneous cells to determine
the most similar records. Next, persons belonging to the same group are matched together
using a distance function. The cell groups are formed to ensure a certain standard is always
maintained for the statistical match. When using a small number of cell groups, the accuracy
of matches can be improved by a properly formulated distance function. A similar approach of
first dividing the datasets into groups of similar households, before doing any actual
matching, is discussed in Sutherland et al (2002).
2.8
Homogeneous groups The variables used to divide person records into homogeneous
groups include age (6 groups), gender (2 groups), income unit expenditure on prescriptions
(4 groups initially, then collapsed to 2 groups), income unit type (4 groups initially, then
collapsed to 2 groups), and concession card status (2 groups). Using these five variables
resulted in 384 cell groups. It was not until income unit type and expenditure on
prescriptions had each been collapsed into two groups, that it was possible to obtain
populated cell groups for all combinations (96 cell groups). While there were other common
variables available (labour force status, number of usual residents in the household and
equivalent income unit decile), these were not used as the more variables used, the less likely
that cells will be populated (i.e not empty).
2.9
Distance function The distance function is a mathematical equation that attempts to more
closely match individuals from the two surveys who fall within the same cell group. It is of the
Mahalanobis form, defined as
(1)
where Sx is the estimated covariance matrix for the X variables. This was calculated using
user-defined weights corresponding to the relative importance given to each matching
variable. The X variables include age, number of usual residents in the household and
equivalent income unit decile. The age variable in the distance function has 16 possible
categories, somewhat more than the 6 categories employed in the cell groups. Two
approaches were considered in implementing this stage of the matching procedure:
unconstrained and constrained matching.
2.10
Unconstrained matching Unconstrained matching is relatively simple and computationally
easy. The approach is to match each HES record to the closest matching NHS record with
replacement. Under this approach it is possible for the same NHS record to be matched with
multiple HES records. Selecting NHS records for matching in this manner ensures that the
"match quality" is high. Table 1 shows the accuracy of the match with respect to the variable
age. Age was a cell group variable and this ensured a certain level of accuracy[6]. The distance
function tightens the match very successfully for the unconstrained method. Consider the age
group 40 to 44 in the matched dataset. 83 percent of the records have been matched to NHS
records with the correct age group.
2.11
The downside is that it can be difficult to match many of the records so, ultimately, the
distribution of the non-matching variables in the matched file can be very different from their
distribution in the original dataset; this "can have a deleterious effect on the validity of the
results of analyzing the matched file" (Cohen 1991 p. 65). The problems with unconstrained
matching become more apparent when working with data at a finer level of disaggregation.
Table 1: Unconstrained matching age allocation






























0-4 100 . . . . . . . . . . . . . . .
5-9 . 90 10 . . . . . . . . . . . . .
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15-19 . . . 88 12 . . . . . . . . . . .
20-24 . . . 38 62 . . . . . . . . . . .
25-29 . . . . . 79 18 4 . . . . . . . .
30-34 . . . . . 12 75 14 . . . . . . . .
35-39 . . . . . 3 12 85 . . . . . . . .
40-44 . . . . . . . . 83 13 4 0 . . . .
45-49 . . . . . . . . 15 72 11 1 0 . . .
50-54 . . . . . . . . 3 12 75 9 1 . . .
55-59 . . . . . . . . 1 3 13 72 11 . . .
60-64 . . . . . . . . 0 1 3 12 84 . . .
65-69 . . . . . . . . . . . . . 89 9 2
70-74 . . . . . . . . . . . . . 7 86 7
75+ . . . . . . . . . . . . . 5 6 89
2.12
As MediSim is expected to utilize data on long-term health conditions in the NHS, we
investigated the distribution of this variable. The NHS shows whether or not individuals have
any of 94 possible long-term conditions. Analysis was done on each of these conditions and
a comparison was made between the total number of cases for the unconstrained matching-
based file and the original NHS data. For each long-term condition, the ratio of the number of
conditions in the matched dataset, relative to the original dataset, was computed with a value
of 1 implying that the unconstrained matched file provided a perfect representation for a
given condition. For all 94 conditions, the ratio using the unconstrained matched file
averaged 0.96, but ranged from 0.24 to 1.32. Such a result was not considered adequate and
alternative methods needed to be developed.
2.13
Constrained matching An alternative to unconstrained matching is constrained matching,
also known as the linear programming method following the work of Barr and Turner (1978)
and subsequently applied by other authors such as Barr, Stewart and Turner 1982, Rodgers
1984 and Cohen 1991. Constrained matching requires the use of all records in the two sets of
microdata to be matched, and thus, it is able to preserve the marginal distributions of the
non-matching variables in each of the two microdata sets. This procedure is adopted to
match each HES record to the closest matching NHS record without replacement. As the linear
programming (LP) method selects records from the NHS without replacement[7], this is
expected to reduce the quality of matches compared to the unconstrained matching. A clear
advantage with this methodology is that it can guarantee that marginal distributions will
remain unchanged.
2.14
The linear programming approach requires the sum of HES and NHS weights to be equal. This
ensures a "balanced" problem. If a weight is interpreted as the number of people a record
represents then an unbalanced problem leads to either people in the HES or the NHS not
being matched. As this method is applied to each of the homogeneous cells, adjusting the
weights of either the HES or the NHS to ensure a balanced solution will change the relative
importance of each cell. The weights in this particular application were always re-aligned to
the NHS population. This means that while marginal distributions will change for the HES
variables, these will remain unchanged for the NHS variables.
2.15
Table 2 provides a measure of the "closeness" of the match, again with respect to the age
variable. The weights that have been attached to the distance function are unchanged from
those used to produce the results in Table 1. Table 2 shows that the closeness of the age
match is not as robust as that of the unconstrained matching. The results are still promising,
with very few records in the HES being matched to NHS records where the age categories are
more than 1 group apart. A similar comparison was made, looking at the closeness of the
matches for income deciles and the number of usual residents in the household (Appendix A).
The income results are quite poor with many HES records being matched with NHS records
more than 2 categories apart, while the number of usual residents in the household shows a
relatively close match.
2.16
In the unconstrained matching section the marginal distributions for the 94 long-term
conditions in the NHS were discussed. The statistically matched file often over or under-
reported the incidence of these conditions. The constrained matching method ensures that
the incidence in the matched file is identical to that of the original NHS file.
Table 2: Constrained matching age allocation






























0-4 100 . . . . . . . . . . . . . . .
5-9 . 87 13 . . . . . . . . . . . . .
10-14 . 11 89 . . . . . . . . . . . . .
15-19 . . . 88 12 . . . . . . . . . . .
20-24 . . . 25 75 . . . . . . . . . . .
25-29 . . . . . 77 20 3 . . . . . . . .
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35-39 . . . . . 1 18 81 . . . . . . . .
40-44 . . . . . . . . 70 19 8 3 . . . .
45-49 . . . . . . . . 12 58 22 7 1 . . .
50-54 . . . . . . . . 4 12 57 22 6 . . .
55-59 . . . . . . . . 1 3 10 59 27 . . .
60-64 . . . . . . . . 0 1 2 15 82 . . .
65-69 . . . . . . . . . . . . . 69 23 8
70-74 . . . . . . . . . . . . . 9 62 29
75+ . . . . . . . . . . . . . 3 8 89
Conclusion Regarding the Statistical Matching
2.17
The purpose of the matching was to create a file structure amenable to family PBS
expenditure. Family PBS expenditure depends on the age, health and card status of
individuals within a family. The variables that have been used in the cell groups and the
distance function attempt to account for these factors.
2.18
Two possible matching procedures have been compared: unconstrained matching, where NHS
records can be matched to HES records with replacement; and constrained matching where
linear programming was used to ensure that marginal distributions of at least the NHS
variables remained constant. Both procedures have the ability to match relatively closely on
the variables common to the two source microdata. Only the constrained matching can
guarantee that marginal distributions will remain unchanged.
2.19
The work undertaken by NATSEM in collaboration with the ABS on statistical matching gave us
a better understanding of the theoretical and practical issues in statistical matching, and how
to evaluate the accuracy of the matched dataset. On this basis, the matched file that was
estimated using constrained matching was selected as the preferred base file for MediSim.
Essentially, the person records in the original NHS were reshuffled into different families
based on the HES family structure, such that information on every family member (which is
essential to modelling the safety net) was available. Given that the original NHS person
records have now been reconstructed into complete families, NATSEM's intention is to use
only the variables from the NHS. With the exception of family structure, individual values in
the NHS are preserved in the statistically matched file[8].
 Imputing short term health conditions
3.1
The inclusion of variables on health conditions in the model's dataset is the necessary first
step to developing a facility in the model to measure health outcomes and to simulate policy
changes with respect to people's health status and need for medicines. It is also essential for
a microsimulation model that seeks to derive estimates of PBS drug usage for those with
particular short term conditions under changing PBS rules. The 2001 NHS does not provide
information on people's short-term (ST) health conditions. The 1995 NHS provides the most
comprehensive data about short-term conditions, and was used to impute such conditions
onto the model population.
3.2
To impute ST conditions, the following tasks had to be undertaken: identify what short-term
conditions need to be imputed; up-rate prevalence rates from 1995 to 2001; develop SAS
code to impute the selected short-term health conditions onto the statistically matched
dataset taking into account a range of explanatory variables; and move from a 2-weekly to an
annual picture of short-term conditions.
Definitions
3.3
Short-term conditions are defined as conditions that are experienced for less than 6 months
or are expected to last for 6 months or less (ABS 1996). Prevalence rate is the number of
current cases or persons having the disease divided by the population at risk (Woodward
2005, pp.12-13).
What Conditions Count As Short-term And Need To Be Imputed
3.4
What specific health conditions are counted as short-term? Asthma, diabetes, arthritis and
epilepsy are typically experienced as long-term conditions while dental problems, injuries,
headaches, cough, colds, sore throat and influenza, and ear pain are typically short term in
nature. In between is a wide spectrum of conditions that are characterised by some
respondents as only short-term, only long-term, or both short and long-term.
3.5
The 1995 NHS has information on the number of persons reporting specific health conditions
and the proportion indicating that the condition is short-term only. We designate as short-
term those conditions where the proportion of 'only short term' as opposed to 'only long-
term' or 'both short and long-term' to the total number of persons is more than 5%.
3.6
Next, we eliminated those short term health conditions for which information is available on
the 2001 NHS, as information was collected on the seven national health priority areas. We30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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the 2001 NHS, as information was collected on the seven national health priority areas. We
used the ICD9 classification of health conditions, as this classification is common to both the
1995 and 2001 health surveys. However, we aggregated some specific conditions. For
example, we combined sciatica, curvature of spine, diseases of the intervertebral disc, and
unspecified back problems into one category — back problems. The main purpose was to
increase the probabilities as when these are too low (and considering the indivisibility of
record weights), it is difficult to accurately impute such probabilities. In summary, the number
of specific conditions to be imputed was narrowed down to some 50 conditions, listed in
Appendix Table B3.
Uprating Short-term Conditions To 2001 Levels
3.7
How did we uprate the prevalence of short term health conditions to 2001 levels, given that
the latest comprehensive information we have is from the 1995 NHS? The most
straightforward way was to assume that the change in the prevalence rate for short-term
conditions was the same as change in the rate of prevalence for comparable long-term
conditions (noting that for most conditions, there is a great deal of overlap between long-
term and short-term conditions). For each short-term condition, we applied the change in
the long-term prevalence rate over the period 1995-2001, to bring up the 1995 short-term
prevalence rate to 2001 levels.
3.8
The underlying assumption is that most conditions have both a short-term and long-term
element, and we expect the rate of change in the long-term element to be in the same range
as the rate of change in the short-term element. We supplemented this with information from
the Australian Institute of Health and Welfare (AIHW) population hospital morbidity data over
the period 1995-2001 for specific health conditions.
3.9
There were many changes in the health surveys between 1995 and 2001, including changes in
the definition and classification of health conditions. The change in the number of (specific)
health conditions over the period could in part be due to differences in survey methodology.
Nevertheless, whatever the reason for the changes in prevalence over the period 1995-2001,
what was important was to reflect these changes in the model base file[9].
Two-week Window for Reporting Short-term Conditions
3.10
In the 1995 health survey, short-term conditions (or recent illness) are identified through an
actions-based approach. Respondents were asked whether they had taken certain types of
action in the previous two weeks, and the medical condition or other reasons for those
actions. A two-week reference period was adopted as a compromise between minimising
respondent recall errors and ensuring sufficient observations were recorded from which
reliable estimates could be produced. The data were collected over a 12-month period so any
seasonality occurring for particular conditions would have been accounted for. In summary,
information from the 1995 NHS can be taken to estimate the prevalence of short-term health
conditions in any two-week period during that year (ABS 1996, pp 121 and 125).
3.11
Although the 2-week period is practical for recall purposes, the relative shortness of this
period has implications for our purposes. While the survey is able to capture information on
all survey respondents that had a long-term condition, it is only able to capture information
on a fraction of the respondents that had a short-term condition in a year. For example,
those experiencing short-term conditions a month back would not be counted.
3.12
The next table shows the distribution of the Australian population by term of health
condition. Nine percent of the 1995 respondents reported having a short-term health
condition (only) within the past 2 weeks whereas, if we were to take an annual picture, the
proportion of respondents that suffered from short-term health conditions sometime during
the past year would be considerably higher. Similarly, the proportion of respondents with no
health condition in 1995 (whether short- or long-term) would be considerably lower than the
16% reported based on the two-week survey window. Comparable figures for 2001 are
presented to indicate the change between the two years.




1995 Long term only or both recent and long-term 13,365 74
Recent only (short-term) 1,625 9
No health conditions (not applicable) 2,890 16
Total population 18,061 100
2001 With a long term condition 14,737 78
Without a long term condition 4,179 22
Total population 18,916 100
3.13
In conclusion, while the 1995 NHS does have the most comprehensive information on short-
term conditions, we need to take note of the limitations of the two-week window for
reporting short-term conditions — particularly when what we actually require for the30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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modelling are annual estimates.
Imputing the Prevalence of Short-term Health Conditions
3.14
Numerous studies have found a link between health and income (see Walker and Abello 2000
and Walker et al 2006 for review of relevant literature). We take concession card status as a
proxy for income. Likewise, there are clear patterns in the distribution of disease by age,
gender and self-assessed health status. Given the foregoing, the imputation of short-term
conditions was based on concession card status, gender, age and self-assessed health
status. Persons were divided into the following age groups, which were set up to represent
differences in the prevalence of health conditions across these age ranges: 0-4, 5-14, 15-
24, 25-39, 40-64, and 65 years and over.
3.15
Overview of imputation process Imputing short-term conditions onto the model
population involved sorting the person records in the model base file by concession card
status, gender, age group and self-assessed health status. For each short-term health
condition, person records were selected at random to 'have' the ST health condition until the
uprated prevalence figures were met.
3.16
Two-monthly prevalence rates Short-term conditions in the 1995 NHS were based on
health conditions persons reported having over the previous two weeks. The prevalence of
short-term (ST) health conditions on a two-weekly basis were obtained from the 1995 NHS
then uprated to 2001 levels. The use of a fortnightly prevalence rate to impute short-term
conditions onto the model dataset implies that we would have to impute 26 times to bring the
fortnightly estimates up to annual estimates.
3.17
Another approach is to scale up or multiply by a number greater than 1.0 the prevalence rates
(expressed as a percentage of the population) before imputing. However the scaled-up
prevalence rates should not exceed 1.0 as a prevalence rate of 1.0 implies that all persons in
the selected group will "get" the health condition. If the rate is greater than 1.0 then the
target prevalence rate will not be achieved as there will not be sufficient number of persons to
be imputed the disease. An inspection of the fortnightly prevalence rates for all short-term
conditions showed that when multiplied by 26/6 (multiplied by 26 fortnights, and divided by
6 months), none exceeded 1.0, so a two-monthly prevalence rate was deemed to be
reasonable.
3.18
To expand the two-week estimate to a two-monthly estimate, prevalence rates were
multiplied by 26/6. The imputation procedure using the two-monthly prevalence rates was
carried out six times, resulting in annual estimates of the prevalence of short-term conditions
in the model population. Each two month imputation was independent of previous
imputations. Doing the imputation this way implies that a person has one chance of getting a
specific short-term health condition every two months. In actuality, some persons do
experience some conditions (e.g. colds) more frequently than that, while other conditions
(such as influenza) might only occur once in a season as infection leads to immunity. In
general, however, we expect this assumption to be reasonable.
3.19
Take as an example, back problems. The two-monthly prevalence rates for this condition are
shown in Table 4 by a person's age group, gender and card status; for purposes of simplicity
we do not present the rates by self-assessed health status. The first figure of 0.03 indicates
that, over a period of two months, we expect 3 percent of male concession cardholders aged
0-14 to be imputed to have a back problem while, for non-concession cardholders (the
general population), the percentage is 1 percent.
3.20
Using two-monthly prevalence rates, the imputation process was done six times, for each
short-term condition, so we end up with annual prevalence rates. Every two months about 3
percent of males aged 0-14 among concessional patients would be imputed to have a back
problem once. Because of the imputation process used, a person could be imputed, at most,
to have a back problem six times in a year.
Table 4: Two-monthly prevalence rate of back problems by concession
card status, 2001 (per 100 population)
Source: NATSEM estimates.
Concessional Concessional General General
Males Females Males Females
15-34 years 0.03 0.01 0.01 0.01
35-49 years 0.09 0.09 0.07 0.16
50-64 years 0.12 0.18 0.15 0.17
65-74 years 0.23 0.18 0.13 0.17
75 years plus 0.12 0.13 0.14 0.05
3.21
Cloning To adequately assign short-term health conditions across the whole population, it
was necessary to clone the NHS records i.e. create multiple records of the same person in the
dataset. Each record in a survey has a weight representing the likelihood of finding persons
with a similar set of characteristics in the Australian population. Records can be duplicated30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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with each clone i.e. each new record having a proportionally smaller weight (maximum weight
was set at 200). The cloning of records with smaller weights enabled us to impute short-term
conditions with greater accuracy.
Conclusion Regarding the Imputation of Short-term Health Conditions
3.22
Short-term health conditions were imputed based on the prevalence in 1995, uprated to
2001 levels, and taking into account the distribution of conditions by concession card status,
gender, age and self-assessed health status. The two-weekly estimates were then
annualized. There are a number of potential limitations in the methodology used, particularly
assuming that the prevalence of short-term conditions over the period 1995-2001 changes
at the same rate as that of long-term conditions. The method of scaling up the prevalence
rates to a two-monthly level and doing the imputation six times to come up with annual
estimates is a modelling simplification, and does not fully replicate the real-life process. For
particular short-term health conditions (such as influenza), that may occur once in a season
rather than several times, the modelling may need to be modified to reflect this. If the data on
prevalence of short-term conditions were to be used for a purpose more directly related to
health, then one would need to be careful in using the imputed values. For the purposes of
MediSim, which is to use the prevalence of short-term health conditions (in addition to actual
data on the prevalence of long-term conditions) to calculate the annual drug usage of
individuals, the limitations of the methodology have a marginal effect on the model and what
it can do.
 Imputing Prescribed Drug Usage
4.1
Data on the use of prescribed medicines is available in the 2001 NHS only for national health
priority areas that are specified by the respondent as long-term. For short-term and non-
priority health conditions, annual drug usage has to be imputed.
4.2
Imputing fortnightly drug usage involved the following steps: (a) estimating the probability of
taking prescribed drugs given that one has a specific health condition; and (b) given that one
takes prescribed drugs, modelling the number and type of drugs taken. Steps (a) and (b) were
done separately for short-term and long-term conditions. Note that by implementing steps
(a) and (b) we are implicitly assuming that there has been no change in the nature of demand
and supply for prescribed medication, including such aspects as demand for new medicine
and change in doctor prescribing patterns, amongst others. Over the period 1993 to 2003,
there has in fact been an annual increase of about 3 percent in PBS scripts per capita (total
PBS scripts divided by the Australian population). However, there is no data on the change
with respect to number of persons using PBS drugs, or number of PBS scripts per person
using PBS drugs, as 2003 is the first year for which we have data on the usage of scripts by all
persons using PBS drugs (prior to 2003, Medicare Australia only monitored the usage of
concession cardholders). Due to the lack of data on the changes in total PBS usage prior to
2003, we adopt a two-step approach: first, we impute drug usage using the 1995 patterns.
Subsequently, we modify the imputed drug usage based on actual data as of 2003.
Imputing the Probability of Taking Prescribed Drugs
4.3
Not all persons who have health conditions take prescribed medication for that condition or
even any medication at all. For each health condition, the 1995 NHS provides information on
the proportion of persons having such conditions that take prescribed drugs[10]. This
proportion varies by the type of health condition (with the proportions being very high for
those with diabetes, most heart conditions, epilepsy, other hereditary diseases of the nervous
system, and contraceptive management). Initially, we considered the possibility of grouping
conditions based on closeness in the proportion of persons taking prescribed drugs. However,
it was hard to find a common pattern and the best option seemed to be to do the allocation
on a specific condition basis.
4.4
We estimated the probability of taking prescribed drugs, given that a person had a specific
health condition, taking into account differences in gender, age, and card status. Card status
is particularly important, as the usage of PBS drugs is much higher for concession
cardholders than non-concession cardholders. Age is also particularly important, as the
oldest and youngest age groups tend to have a higher proportion taking prescribed drugs.
Imputing the Number and Types of Drugs
4.5
After the proportion of persons (by specific health conditions) taking prescribed drugs had
been established, the next step was to identify the number and types of prescribed drugs
taken for each specific health condition. The variables taken into account include type of
health condition, gender, age and card status.
Converting Fortnightly to Annual Drug Usage
4.6
There was no need to adjust the imputed drug usage for short-term conditions, due to the
approach taken of scaling up the prevalence levels to a two-monthly period and
implementing the imputation procedure six times. To convert the imputed fortnightly long-
term drug usage into an annual figure, each person's script for a long-term condition was
multiplied by 12, for each type of drug used. This presumes that a person with a chronic
condition requiring the use of prescription drugs will use the drug(s) regularly throughout the30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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year. This also assumes that scripts are issued for a 1-month's supply, which is generally the
case for chronic conditions in Australia.
4.7
The actual (as against imputed) drug usage for priority conditions available on the NHS was
summed up and converted to an annual figure using a factor of 12. This, together with the
imputed scripts for non-priority conditions, represents the total number of scripts used
annually by the total Australian population excluding Veterans[11].
PBS Scripts: Aligning Imputed Drug Usage to Administrative Data
4.8
After annual estimates of total prescribed drug usage had been imputed, we then shifted the
focus to PBS prescriptions. In Australia, total prescribed drug usage includes three types of
medicines:
scripts for drugs with a cost to government under the PBS (known elsewhere as 'benefit'
drugs and called Group 1 scripts in MediSim);
scripts for PBS-listed prescribed medicines not attracting a government subsidy — that
is, scripts with a price below the PBS copayment level (below copayment drugs — Group
2 scripts); and
scripts for prescribed drugs not listed under the PBS (private medicines — Group 3
Scripts).
4.9
The focus of the model is on PBS benefit or Group 1 drugs only so the alignment procedure
selects and then aligns PBS scripts to administrative numbers.
4.10
The total annual scripts (imputed and actual) were summed up for each of the 19 drug
classes in MediSim (see Appendix Table B1 for drug classes used in MediSim). For
benchmarking purposes, we obtained administrative data on the number of PBS scripts per
year per person by concession card status, gender, five-year age group and drug class for the
year 2003 (see figure 2)[12]. We also had administrative data on the number of persons using
PBS drugs, by the same categories.
Figure 2. Distribution of annual PBS scripts per person, 2003 
Data source: Medicare Australia 
Note: See Appendix Table B1 for listing of drug classes. The data underlying this graph are in Appendix Table C1.
4.11
For each of the 19 drug classes, Figure 2 shows the proportion of PBS beneficiaries using only
1 script per year, 2 scripts per year, and so forth. Particular drug classes, such as drug class30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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18 (direct acting antivirals) and drug class 14 (antibiotics) are used only once a year by most
persons, whereas other drugs taken for chronic conditions have higher annual scripts, with
peaks at 12 scripts and 24 scripts per year.
4.12
Total script usage may be viewed as the product of number of persons using a particular drug
type, and number of scripts used per drug type. To validate the data on drug usage, we
examined this on two fronts. First, we looked at the number of persons taking drugs, and
second, we looked at the number of scripts per person. Steps were taken to more closely
align the imputed drug usage to administrative numbers.
4.13
Number of persons taking drugs The total number of scripts in the model base file looked
reasonable. However, when looking at the number of persons using drugs and their average
number of scripts, there were large discrepancies between what we had in the model, at that
stage, and comparable administrative numbers from Medicare Australia[13]. In particular,
administrative data showed many more persons using PBS medicines than we had estimated
in the model, for most (14 out of 19) drug classes, particularly for the very young and the
very old. The exceptions were these five drug classes: anti-inflammatories, vasodilators beta
blockers, calcium channel blockers, anxiolytics and hypnotics and direct acting antivirals[14].
4.14
This discrepancy may be attributed in part to our methodology of imputing the probability
that persons with specific health conditions take drugs simply based on 1995 usage rates. As
discussed previously, due to changes in the coverage of the 2001 national health survey there
is no data on the change between 1995 and 2001 in the number of persons taking drugs with
specific health conditions. The discrepancy may also be attributed to the non-inclusion of
institutionalised persons in the NHS data (with the NHS survey only covering people living in
private dwellings)[15]. Supporting this assumption about the institutionalised, the "lack of
persons" was true for most drug classes, even those that cater primarily to priority conditions,
for which actual drug usage was available in the 2001 NHS. This includes asthma medications,
diabetes medications, heart condition related drugs, mental- health related therapies and
cancer drugs.
4.15
In conclusion, to take into account increases in the rate of medication between 1995 and
2001 as well as the non-inclusion of institutionalised persons in the NHS data, we revised the
methodology to increase the proportions of persons taking medication for the 14 drug
classes, until they matched administrative numbers. These individuals were taken from the
group of persons having health conditions that required the use of those particular drugs.
4.16
Finally, for each drug class, we identified persons in the base file using the drug, listed their
scripts classified by their card status-gender-age group, and designated (at random) some
as PBS scripts until we had sufficient number of PBS users to match administrative numbers
for each drug class-card status-gender-age group. Note that since persons may take
multiple drugs, persons in the base file may have some of their scripts designated as PBS
scripts, and others designated as non-PBS scripts.
4.17
Number of scripts per person Next we looked at the number of annual scripts per person in
the model base file and compared this with administrative data from Medicare Australia. The
administrative data shows, for each drug class, card status, gender and age group, how many
persons used one script, two scripts, and so forth on an annual basis. To make this clearer we
present an extract of the data on the distribution of scripts in Table 5. The table shows the
distribution of PBS scripts of males with concession card status, using anti-inflammatories
(drug class 1) in 2003. For example, the first cell in the table shows that 231 or the majority
of young male children aged between 0-4 years used only one script in 2003.
4.18
The alignment procedure was as follows: for each of the 19 drug classes, by card status,
gender and age group, scripts in the model base file were ranked from highest to lowest. This
is compared with administrative data on the distribution of scripts. The administrative data on
the distribution of scripts per person by drug class was used to revise the initial level of PBS
scripts. In part, this revision of scripts may be viewed as a refinement to the crude method
taken of giving each person with a long-term condition 12 scripts to convert the two-weekly
drug usage into an annual figure.
Table 5: Example on distribution of PBS scripts per person (anti-
inflammatories, males with concessional card status) by age group, 2003 
Data source: Medicare Australia.
Number of persons by age group
No. of scripts 0-4 5-14 15-24 25-34 35-64 65+
1 231 3,426 21,342 40,650 86,569 85,152
2 32 335 3,092 10,005 35,847 41,216
3 6 119 860 4,194 20,611 27,669
4 9 70 415 2,344 15,746 23,305
5 6 37 198 1,368 10,463 16,614
6 2 24 130 908 8,504 14,748
7 2 19 98 706 7,417 13,763
8 1 10 34 452 6,172 12,110
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10 1 7 99 867 12,238 22,213
11 0 7 88 597 6,746 12,779
12 0 19 54 489 5,960 11,315
13-24 0 12 51 413 7,075 14,677
25-36 0 0 2 48 363 330
37+ 0 0 0 4 45 26
Total 291 4,096 26,500 63,465 231,113 311,715
Concluding Note on Imputation of Drug Usage
4.19
The methodology to impute drug usage for short-term and non-priority health conditions in
the model was a long process. The initial steps, particularly using the 1995 national health
survey, implicitly assumed no change in usage since 1995. However, subsequent steps —
particularly aligning the imputed drug usage to actual data — compensated for this deficiency
in the methodology due to data limitations. Because of the alignment method adopted, the
designated PBS scripts in the model very closely approximate the distribution of (actual)
administrative data on total scripts by drug class and the distribution of scripts per person,
by drug class, concession card status, gender and age group. This represents a substantial
advance in the data on drug usage. (Figures comparing the distribution of drug usage in the
model base file with administrative data on actual PBS scripts are provided in Appendix tables
C2 to C4.) In the previous version of the model, while the aggregates per drug class were
accurate, we were less certain about whether scripts per person were reasonable. Similarly,
the distribution of PBS users in the model now closely approximates the distribution of PBS
users based on administrative data. Note that in order to more closely align scripts at the
person level with administrative data, the model's records had to be cloned further, with each
record having a maximum weight of 100 or less.
 An application of the model
5.1
Since the model was updated in 2004, MediSim has been used for number of applications on
the distributional impact of the PBS in general and the PBS safety net in particular (Brown et al
2005a, Brown et al 2005b and Brown et al 2006). The model has also been used to quantify
the effect of changing the rules of the PBS in various ways — such as greater differentiation in
setting copayments, means-testing, changes in the indexation of copayment increases, and
changes to the PBS pricing system.
PBS Policy Settings
5.2
The policy settings of the Pharmaceutical Benefits Scheme for recent years are given in table
6. The figures for 2005 show that:
for general patients the maximum contribution for each PBS medicine is $28.60, the
government paying for the rest; and
for concessional patients an additional subsidy applies, so that their maximum
contribution is only $4.60 per PBS medicine.
5.3
Although some PBS medicines can cost over $100, patients are required to pay at most
$28.60. If the full price of the drug is below $28.60 (or $4.60) then the patient pays the full
price — these drugs are known as 'below copayment' drugs and are not included in PBS
statistics.
5.4
Families requiring a lot of medicines in any one year are protected by the PBS safety net. Once
a family that does not have concessional benefits records spending beyond the safety net
limit of $874.90 in a calendar year, they are required to pay only $4.60 for each further PBS
medicine within the same year. For concessional patients there is no cost once their families
have a record of spending beyond the safety net limit of $239.20 in a calendar year. In this
case the government pays the full price of all further PBS medicines prescribed within the
year. Each year, on 1 January, the safety net for each family is reset to zero for administrative
purposes.
Table 6: Policy settings of the Pharmaceutical Benefits Scheme, 2001-06
1/1/2001 1/1/2002 1/1/2003 1/1/2004 1/1/2005 1/1/2006
$ $ $ $ $ $
Copayment —
Concessional
Below safety net 3.5 3.6 3.7 3.8 4.6 4.7
Above safety net 0 0 0 0 0 0
Copayment — General
Below safety net 21.9 22.4 23.1 23.7 28.6 29.5
Above safety net 3.5 3.6 3.7 3.8 4.6 4.7
Safety net threshold
Concessional 182.0 187.2 192.4 197.6 239.2 253.8
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No. of safety net scripts
Concessional 52 52 52 52 52 54
General 31 31 31 31 31 33
Overview
5.5
There were a number of significant changes in 2005 that affected the Australian PBS.
Foremost was a 21 percent increase in patient copayments and safety nets starting 1 January
2005, relative to the previous year. Another measure that came into force was that the price
of all drugs in a reference-pricing group (or medicines that produce similar health effects)
were required to drop 12.5 percent once one of them came off patent and the first generic
version became available. Further, starting 2006, the safety net thresholds were legislated to
increase by two scripts in each year for four years. This adds to the safety net threshold the
equivalent cost of eight scripts by 2009.
5.6
In 2005-06, total PBS prescriptions declined by 1.2 percent relative to the previous financial
year. This is the first time since 1990-91 — coinciding with another significant copayment
increase — that PBS scripts showed any decline. In 2005-06 some 172 million scripts were
estimated to be subsidised under the PBS at a total cost of $6.6 billion[16], with 82 percent of
this expenditure being met by Government and 18 percent from patient contributions.
5.7
The next sections describe which Australian families benefited most from government outlays
on the PBS. The results for 2005-06 are presented by income quintile, age group, family type
and lifecycle group.
5.8
Income quintile is derived from equivalent disposable annual family income based on the new
OECD equivalence scale. The quintiles are population based in that each person has been
ranked by the equivalent disposable annual income of their family and the population divided
into fifths. Quintiles have been calculated separately for concessional, general and all
persons. Thus, the bottom quintile of concessional patients is the bottom 20 percent of
individuals who live in families that have a concession card, after ranking by the equivalent
disposable annual income of their family. Disposable annual income per family is simply
gross annual income of the family minus income tax. An equivalence scale is used to adjust
the income of each family, in an attempt to place families with a differing number of mouths
to feed on a more equal basis. The equivalence scale used is the new OECD scale, which gives
a value of 1 to a single adult, 0.5 to a second adult and 0.3 to each dependent child.
5.9
Family type is defined in terms of whether or not there are dependent children in the family
and whether or not there are one or two adults in the family e.g. couple versus sole parent or
single person family. Dependent children are defined as children aged 0 to 14 years, or aged
15 to 24 years and engaged in full-time study, or non-fulltime students aged 15-20 who are
considered dependents. Lifecycle group is based on family type plus age of the head of the
family.
5.10
Costs and script volumes are averaged over the total population, not just families who used
PBS medicines in 2005-06. With improved modelling of the safety net in the updated
MediSim, it is now possible to report annual figures — thus the distributional impact of the
PBS reported in this paper are annual and not the fortnightly window previously reported in
Harding et al (Harding et al 2004).
Distributional Outcomes
5.11
Income group About 41 percent of all PBS government outlays are directed towards the
poorest one-fifth of Australians. In sharp contrast, just under 8 percent of total PBS outlays
are received by the most affluent one-fifth of Australians. This highly pro-poor pattern of
outlays reflects the higher subsidy received by persons in lower income families (figure 3).
Figure 3. Estimated percent of PBS outlays received by each income quintile of Australians,
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5.12
Concession card status by age group While partly related to income, age is another key
driver of the receipt of PBS benefits. Figure 4 emphasises how outlays on concessional
patients dominate the system. It also illustrates clearly how negligible are outlays on general
patients aged 60 years and above.
5.13
During childhood and adolescence, between two-thirds and three-quarters of all PBS
government outlays are received by concessional families, with the remainder being directed
at children living in families that are not within the social security and family payments safety
net.
5.14
During the years of the 30s, about two-thirds of all PBS outlays go to those living in
concessional families, with this proportion falling to its lowest level of about half of all PBS
outlays when individuals are in their late 40s and early 50s. During this period of the life
cycle, Australians are relatively more likely to have become 'empty nesters', be in employment
and not be dependent on the welfare or other benefits that provide a passport to the
concessional PBS card. However, this profile changes dramatically during the retirement years
after age 55. From age 65 onwards, about 95 percent of all PBS outlays directed at this age
group go to concessional families, reflecting the high rates of receipt of the age pension and
the extension in recent years of PBS concessional status to most self-funded retirees. In
addition, of course, the pattern of rising total PBS outlays across the life cycle is a product of
increasing rates of morbidity as age increases, reflected in the steady rise in script numbers
after the age of 20 years.
5.15
The pattern of PBS benefits generally rising steadily with increasing age stands in sharp
contrast to the underlying population distribution. Of every six dollars spent by Government
on the PBS, one dollar was received by a person aged 75 years or more. And yet while this age
group received about 17 percent of total PBS government outlays, they represented only 5.6
percent of Australians. Conversely, Australians aged 20 to 24 received only 2.4 percent of
total PBS government outlays but represented 7 percent of the Australian population.
Figure 4. Estimated percent of PBS outlays received by age group, 2005-06
5.16
Concession card status by income group Another possible perspective is to separate the
concessional and general populations, and then calculate income quintiles for each group
(rather than for the population as a whole, as done above). Thus, in this case, 'concessional
quintile 1' equates to the poorest 20 percent of Australians living in families that receive
concessional pharmaceuticals, while 'general quintile 1' represents the poorest 20 percent of
Australians living in families that do not receive concessional pharmaceuticals.
5.17
Figure 5 traces PBS government outlays received as a percentage of disposable income, for all
Australians and for those who live in concessional and general families. Government outlays
per family (expressed as a proportion of family disposable income) decrease significantly as
family incomes rise. The poorest one-fifth of families receive government benefits amounting
to 6.6 percent of family disposable income, compared to 0.4 percent for the top 20 percent.
This pro-poor pattern of expenditure occurs for both concessional cardholding families and
non-concessional families. Total expenditure by families and the government on PBS
subsidised medicines amounts to 8.1 percent of the annual disposable income for the lowest
concessional income quintile families, decreasing to 3.4 percent for the top concessional
quintile, and for general patients from 1.6 percent to 0.5 percent.30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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Figure 5. Estimated PBS subsidy as a proportion of disposable family income, 2005-06
5.18
Concession card status by family type One of the important redistributive effects of health
outlays is the support offered to families with children (ABS 2001b, Harding et al 2002).
Accordingly, Figure 6 and Table 7 show the estimated value of the PBS subsidy received by
different types of families in Australia.
Figure 6. Estimated distribution of PBS subsidy by family type, 2005-06
5.19
Families with children are estimated to spend between 0.3 and 0.4 percent of their annual
disposable income on PBS medicines in 2005-06. This seems to occur irrespective of whether
or not the family is a couple or sole parent family, are concessional cardholders or not, and
independently of the number of children.
5.20
The majority of couple with children families (80 percent) do not have concessional status and
receive Government subsidies to the value of only 0.5 percent of their annual family income.
In contrast, sole parent families typically have concession cards and receive a much higher
government subsidy of $507 on average per annum per family, which is equivalent to 1.8
percent of disposable family income. Sole parent families receive an estimated 3.2 percent of
total government outlays on the PBS while couples with children receive 14.9 percent.
Table 7: Estimated impact of the PBS by family type, 2005-06
Couples Sole Couples Single All




Disposable annual income per family (1) $ 58,039 31,400 39,790 26,552 36,638
Family spending per year on PBS drugs (2) $ 203 83.8 220.4 73.5 137.3
Family spending % of income (2/1) % 0.3 0.3 0.6 0.3 0.4
Govt subsidy per family on PBS drugs (3) $ 487.4 455.5 1,109.00 347.1 569.2
Government subsidy % of income (3/1) % 0.8 1.4 2.8 1.3 1.5
% of all PBS govt. subsidy received by this % 14.9 3.2 48.9 33 10030/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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group
Total PBS expenditure per family (2+3) $ 690.4 539.3 1329.4 420.6 706.5
Total PBS spending % of income (2+3)/1 % 1.2 1.7 3.3 1.6 1.9
No. of families '000 2,170 469 2,550 5,157 10,347
Concessional patients
Disposable annual income per family (1) $ 33,560 27,918 25,985 18,063 22,903
Family spending per year on PBS drugs (2) $ 136.6 74.8 198.6 106.7 132.7
Family spending % of income (2/1) % 0.4 0.3 0.8 0.6 0.6
Govt subsidy per family on PBS drugs (3) $ 1141.7 507.2 2062 796.7 1161.9
Government subsidy % of income (3/1) % 3.4 1.8 7.9 4.4 5.1
% of all PBS govt. subsidy received by this
group
% 7.4 2.7 40.5 29.6 80.2
Total PBS expenditure per family (2+3) $ 1278.3 582 2260.6 903.4 1294.6
Total PBS spending % of income (2+3)/1 % 3.8 2.1 8.7 5 5.6
No. of families '000 424 371 1,097 2,016 3,907
General patients
Disposable annual income per family (1) $ 63,975 44,539 50,218 31,998 44,973
Family spending per year on PBS drugs (2) $ 219 117.8 236.9 52.2 140.1
Family spending % of income (2/1) % 0.3 0.3 0.5 0.2 0.3
Govt subsidy per family on PBS drugs (3) $ 328.8 260.3 389 58.6 209.5
Government subsidy % of income (3/1) % 0.5 0.6 0.8 0.2 0.5
% of all PBS govt. subsidy received by this
group
% 7.6 0.5 8.4 3.4 19.8
Total PBS expenditure per family (2+3) $ 547.8 378.1 625.9 110.8 349.6
Total PBS spending % of income (2+3)/1 % 0.9 0.8 1.2 0.3 0.8
No. of families '000 1,746 98 1,453 3,142 6,439
5.21
In stark contrast, couples without children spend much more, both in terms of absolute
dollars and as a proportion of their income, on PBS medicines than any other family type. This
is true for both concessional and non-concessional families. In addition, this family type
receives more government dollars per family — the government subsidy on PBS medicines for
concessional couple only families amounts to 7.9 percent of family disposable income and
0.8 percent for general couple families. Thus, this family type invests heavily in prescribed
medicines while receiving nearly 50 percent of total government expenditure on the PBS. As
shown in the next section, this result is driven by the high proportion of aged couples
without children in this group.
5.22
As expected, the pattern of expenditure for single persons differs significantly by
concessional cardholder status. About 60 percent of all singles will not possess a concession
card and therefore are likely to receive an extremely low PBS subsidy across the year (less
than $60). Consequently, even though single person families without concession cards
represent about 30 percent of all Australian families, they receive only 3.4 percent of total
government PBS outlays. This group of individuals also have the lowest user-contribution,
averaging an annual expenditure on PBS subsidised drugs of only $52 (i.e. $1 per week).
5.23
Concessional single person families are, however, the second largest user group of PBS
medicines, receiving nearly 30 percent of all government PBS expenditure and contributing a
further $107 per person per year in the costs of PBS medicines.
5.24
Concession card status by lifecycle group If PBS expenditure is to be seen as an
investment in the future health and productivity of the nation then what are the outlays on
PBS medicines by families and government in terms of stage in the lifecycle? As Figure 7 and
Table 8 indicate, the PBS has major effects across the lifecycle.30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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Figure 7. Estimated distribution of PBS subsidy by lifecycle group, 2005-06
5.25
The biggest consumers of medicines are elderly couples and singles, whose estimated total
PBS expenditures per family are over $2500 and around $1300 respectively. Over 90 percent
of these elderly families access PBS medicines at concession rates. While these two groups
represent 17 percent of all Australian families, they receive over half of all Government
outlays on the PBS. Given their relatively low incomes, this subsidisation represents a
significant welfare transfer — 8.9 and 6.9 percent of disposable annual family income.
5.26
In contrast, single persons aged less than 35 years spend the least on PBS medicines,
matched by relatively low government subsidisation ($20 for general patients and $187 for
concessional patients). Similarly, young couples are the second lowest investors in PBS
medicines but it is this group that receive the lowest share of government subsidies of any
lifecycle group. Just over one-fifth of young singles are concession cardholders — whereas
only 9 percent of young couples are entitled to the reduced concessional rates.
5.27
Both expenditure by families with children and government outlays increase as the children
grow older and family size increases. Couple families where the eldest child is aged 15-24
years and who have a concession card are expected to have a total expenditure of around
$1656 in 2005-06 on PBS subsidised medicines and general families $859.
5.28
Summary The description of distributional outcomes indicate that the PBS is highly
progressive, with two-fifths of total PBS outlays being directed at the poorest one-fifth of
Australians. There are also pronounced distributional effects by age and over the life cycle.
Table 8: Estimated impact of PBS by lifecycle group, 2005-06
Single Couple Couple, Couple Couple Couple Couple Single
<35yrs only,
head














$ 27,699 53,670 54,573 57,912 60,670 36,553 29,201 18,771
Family spending on
PBS (2)
$ 19 48 111 188 295 276 265 165
Family spending %
income (2/1)
% 0.1 0.1 0.2 0.3 0.5 0.8 0.9 0.9
Govt PBS subsidy per
family (3)
$ 57.8 104.4 278 431 734.2 949.1 2323 1132
Govt subsidy % of
income (3/1)
% 0.2 0.2 0.5 0.7 1.2 2.6 8 6
% of all PBS govt
subsidy received by
this group
% 2.7 0.6 1.6 6.5 7 11 31.6 21.3
Total PBS family
spending (2+3)
$ 76.8 152.4 389 619 1029.2 1225.1 2588 1297
Tot. spending %
income (2+3)/1
% 0.3 0.3 0.7 1.1 1.7 3.4 8.9 6.9
No. of families '000 2,469 418 430 1,118 621 646 769 1,009
Concessional
patients
Disp. annual family $ 19,831 28,966 30,173 33,822 34,929 24,180 26,607 17,69330/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost




$ 29 66 95 129 171 188 219 158
Family spending %
income (2/1)
% 0.1 0.2 0.3 0.4 0.5 0.8 0.8 0.9
Govt PBS subsidy per
family (3)
$ 187.4 476.8 742.6 1063.6 1485.4 1746.5 2422.8 1200.5
Govt subsidy % of
income (3/1)
% 0.9 1.6 2.5 3.1 4.3 7.2 9.1 6.8
% of all PBS govt
subsidy received by
this group
% 1.9 0.3 0.8 3.4 3.2 7.9 29.2 20.6
Total PBS family
spending (2+3)
$ 216.4 542.8 837.6 1192.6 1656.4 1934.5 2641.8 1358.5
Tot. spending %
income (2+3)/1
% 1.1 1.9 2.8 3.5 4.7 8 9.9 7.7




$ 29947 56224 59353 63841 67625 44060 48746 31947
Family spending on
PBS (2)
$ 16 46 114 202 328 329 613 244
Family spending %
income (2/1)
% 0.05 0.08 0.2 0.3 0.5 0.7 1.3 0.8
Govt PBS subsidy per
family (3)
$ 20.7 65.9 187 275.3 531.2 465.2 1571.5 294.3
Govt subsidy % of
income (3/1)
% 0.1 0.1 0.3 0.4 0.8 1.1 3.2 0.9
% of all PBS govt
subsidy received by
this group
% 0.7 0.3 0.8 3 3.8 3 2 0.4
Total PBS family
spending (2+3)
$ 36.7 111.9 301 477.3 859.2 794.2 2184.5 538.3
Tot. spending %
income (2+3)/1
% 0.1 0.2 0.5 0.7 1.3 1.8 4.5 1.7
No. of families '000 1,921 379 360 897 489 402 90 76
 Summary and conclusion
6.1
Considerable challenges face modellers attempting to construct health microsimulation
models. This article has described a number of steps taken to overcome the 2001 NHS survey
limitations as the main base file for MediSim, a model of Australia's Pharmaceutical Benefits
Scheme. First, we statistically matched the NHS with another survey, to create synthetic
families and get a complete record for every individual within each family, as family level
information is needed to model PBS safety nets. The statistical matching allowed the retention
of the health information available on NHS 2001, whilst borrowing the family structure from
another survey. Next, we imputed short-term health conditions based on detailed
information in the previous (1995) NHS and converted the two-weekly prevalence rates
derived from the 1995 survey's two-week recall period to annual figures. Finally, we imputed
annual drug usage for short-term and non-priority long-term health conditions. These initial
estimates were then aligned to administrative data on PBS benefit drugs.
6.2
The application of statistical matching methods and use of complementary data sets
significantly improved the usefulness of the 2001 NHS as a base dataset for MediSim, and
enabled improved modelling of the PBS safety net. These enhancements to the national health
survey have improved the capability of MediSim as a microsimulation tool for policy-makers,
the pharmaceutical industry and health researchers.
6.3
This article also illustrated some of the outputs that can now be derived from the MediSim
model, and this analysis clearly demonstrates that the PBS has pronounced distributional
effects. The Scheme is highly progressive, with two-fifths of total PBS outlays being directed
at the poorest one-fifth of Australians. There are also highly differential effects by age and
over the life cycle.
6.4
While much work has been undertaken to enhance the model's main data base, there is still
scope for possible future improvements and extensions of the model with respect to its base
data as well as applications.
6.5
To date, the primary utility of the model has been based on its capability to estimate patient
and government expenditures on PBS medicines based on various price and copayment
assumptions, as well as to estimate the corresponding effect on families belonging to various
income groups. The introduction of diseases into the model's dataset opens the possibility of
using these health measures in some way, for example, to examine options that raise
copayment thresholds for general patients but simultaneously protect the chronically ill
through safety net provisions.30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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6.6
Over the medium-term, the current methodology of using patterns in the 1995 health survey
to impute drug usage will become outdated. One way to update the methodology is to utilise
administrative data on usage of PBS scripts and number of persons using PBS scripts, that is
available starting 2003. As the administrative dataset does not have any information on the
underlying health conditions for which the drugs are being taken, this could be
supplemented by developing a concordance between specific health conditions and types of
drugs taken for these conditions.
6.7
Over the long-term, statistical matching of the national health survey with administrative
datasets, may provide the solution. In 2006, the Australian Bureau of Statistics started looking
into statistically matching the census with administrative data on births and deaths, long-
term migration and national disease registers. In the years to come, the possibility of
statistically matching surveys, particularly the health survey, with administrative data, may
become a reality.
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Notes
1 STINMOD/01a is NATSEM's static microsimulation model of the Australian tax and transfer
system, based on the 1998-99 Household Expenditure Survey (HES).
2 The Australian health system has identified 7 national health priority areas (NHPAs),
including arthritis and musculoskeletal conditions, asthma, cancer control, cardiovascular
health, diabetes mellitus, injury prevention and control, and mental health. The diseases and
conditions targeted under the NHPA initiative were chosen because they currently impose
high social and financial costs on Australian society, and through appropriate and focused
attention significant gains in the health of Australia's population can be achieved.
3 The Australian Bureau of Statistics defines an income unit as 'one person or a group of
related persons within a household, whose command over income is assumed to be shared.
Income sharing is assumed to take place within married (registered or de facto) couples, and
between parents and dependent children' (ABS 2001).
4 NATSEM was given approval by the ABS to conduct the statistical matching, and as part of
the approval process, a joint ABS-NATSEM Technical Working Group on Statistical Matching
was formed.
5 Rodgers (1984) gives a detailed description of statistical matching, as do Rassler (2002),
Radner et al (1980), Cohen (1991), Sutherland et al (2002) and Moriarty and Scheuren (2001).
6 The results are based on unconstrained matching where the distance function used weights
of 0.5 for age, 0.25 for equivalised income unit decile and 0.25 for the number of usual
residents in the household.
7 For the LP approach each record was "exploded" so that a record was repeated to the extent
of its weight. The selection without replacement refers to this "exploded" data set.
8 For our purposes, this only posed a problem with respect to the family income variable. As
persons had been reconstructed into synthetic families, whilst retaining all original NHS
variables, persons belonging to the same family had different family income values. To have a
consistent family income, we averaged the income within each family. This average value was
used to rank persons into income quintiles. Note however that the situation would be the
same for any variable which relates to the whole family (and should thus be the same across
the family), e.g. rurality, SEIFA.
9 For selected long-term conditions, the ABS has made a study of the comparability of the
1995 and 2001 surveys (ABS 2003b). For some conditions, such as heart and circulatory, they
have indicated that each successive survey has improved the breadth and specificity of
questioning for heart and circulatory. For mental conditions, a greater level of public
awareness (and acceptance) may have influenced the higher rates of disclosure of mental
health conditions.
10 For most health conditions (except diabetes, heart problems, depression, psychoses, and
epilepsy and a few other conditions) a large proportion of persons did not report using any
prescribed medication over the previous two weeks in the 1995 NHS. One reason for this
could be that not all persons who have a long-term condition currently have an acute episode
of that condition, in which case they may opt to take their medication less frequently or not at
all. Other reasons could be that prescribed medication is not appropriate for that condition,
or that non-prescribed medicine or other types of treatment are used to manage that
condition.
11 Veterans were excluded from the model as there is a scheme that parallels the PBS, called
the Repatriation Pharmaceutical Benefits Scheme (RPBS) that is separately administered for30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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Australian war veterans and their dependants.
122003 is the first calendar year for which Medicare Australia had data on the distribution of
scripts per person by gender, age group and drug classification for both concession
cardholders and non-cardholders. Previous to this, data were only collected on concession
cardholders that had not yet reached the safety net.
13 Medicare Australia was previously known as the Health Insurance Commission (HIC).
14 Related information on general practice activity (Britt et al 2004) shows that for four out of
the five drug classes listed, there was a decrease in medication rates (albeit over a slightly
different time period, 1998 to 2004), which is consistent with the finding that for these
particular drug classes, there were sufficient number of persons taking medications.
15 The institutionalised include those in hospitals and in homes for the aged and disabled.
While we have no data on their drug usage, we expect this to be much higher than the drug
usage of persons not living in those institutions.
16 Actual data for 2005-06 are slightly different from NATSEM estimates: at 167 million
scripts (instead of 172 million) and total cost of A$6.7 billion (instead of A$6.6 billion).
 Appendix
A Statistical matching tables
Table A1: Quality of the match: number of usual residents variable
NHS HES number of usual residents
1 2 3 4 5 6
Unconstrained 1 93 7 . . . .
2 7 90 3 0 0 0
3 3 9 80 7 1 1
4 1 3 7 86 2 1
5 1 2 3 13 79 2
6 3 1 6 11 14 65
Constrained 1 81 14 3 1 0 0
2 4 82 10 3 1 0
3 2 18 61 18 1 0
4 1 7 12 72 7 1
5 1 1 2 16 67 14
6 2 1 2 3 20 72
Table A2: Quality of the match: equivalent income decile variable
HES equivalent income unit decile
NHS 1 2 3 4 5 6 7 8 9 10
Unconstrained
1 76 20 4 0 0 . . . . .
2 13 75 9 3 0 0 . . . .
3 6 6 73 9 4 1 0 . . .
4 0 1 5 72 16 5 1 0 0 0
5 0 1 3 11 70 12 3 0 0 0
6 . 0 1 2 7 82 5 2 1 0
7 0 0 . 0 1 8 85 3 2 0
8 . . . . 0 0 4 87 5 4
9 . . . . 0 0 0 3 88 9
10 . . . . . 0 . 0 3 97
Constrained
1 35 10 7 12 14 12 3 2 1 3
2 12 31 17 16 9 7 3 1 2 3
3 5 11 28 15 16 11 2 2 3 6
4 3 7 2 23 15 12 9 6 8 15
5 4 6 3 4 23 13 11 12 11 13
6 3 6 4 4 7 31 16 12 9 9
7 2 7 4 6 5 8 42 13 6 6
8 2 5 4 5 4 5 9 47 13 7
9 1 3 5 8 6 5 8 7 46 12
10 1 1 4 8 7 3 5 5 12 54
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4 Vasodilators & beta blockers
5 ACE inhibitors
6 Angiotensin IIs
7 Calcium channel blockers
8 Cholesterol & triglyceride reducers
9 Analgesic medications
10 Antipsychotics







18 Direct acting antivirals
19 All other medications
Table B2: Health conditions in MediSim 
Note: NHPA = National Health Priority Area
1 NHPA Arthritis Rheumatoid arthritis
Osteoarthritis
Arthritis NEC
2 NHPA Asthma Asthma
3 NHPA Diabetes Diabetes Mellitus — Type 1
Diabetes mellitus — Type 2
Diabetes unspecified










Ill-defined symptomatic heart condition
Cerebrovascular disease





Body image & eating disorders
Alcohol and drug dependence
Mental retardation specific delays in
development
6 NHPA Cancer Skin cancer
Breast cancer
Neoplasms NEC
7 NHPA Injury poisoning Complications surgical NEC
Fractures




Entry of foreign bodies
Burns and scalds
Poisoning other than by food
Other injuries
Injuries type not stated
8 Musculoskeletal system Back problems
Other diseases musculoskeletal30/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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Osteoporosis
Rheumatism
Absence of limbs or parts
Musculoskeletal deformities
9 Other endocrine Thyroid disease
Gout
Obesity
Other endocrine and immune diseases
High blood sugar
High cholesterol
10 Respiratory system Bronchitis/ Emphysema
Sinusitis
Cough or sore throat




11 Eye & adnexa Blindness not corrected glasses







12 Ear & mastoid Otitis media
Deafness (complete/ partial)
Ear pain
Other diseases ear & mastoid proc
13 Nervous system Epilepsy
Other diseases nervous system
Migraine
Paralysis
Other hereditary diseases nervous
system
14 Infectious diseases Herpes
Tinea
Other infectious diseases





Other diseases digestive system
16 Genito-urinary Kidney diseases
Other diseases urinary system
Other diseases genital system
Disorders of menstruation
17 Skin subcutaneous tissue Skin rash NOS
Eczema dermatitis
Acne
Other diseases skin and subcutaneous
tissue
Psoriasis
18 Diseases of the blood Diseases of blood
19 Complications childbirth Complications of pregnancy etc









Headache due to stress
Headache unspecified or trivial
Virus
Other symptoms ill-defined conditions
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22 Congenital conditions Congenital anomalies
23 Disability nec Speech impediment NEC
Blackouts loss of cons NEC
Missing organs NEC
Table B3: Short term health conditions imputed in MediSim
Musculoskeletal system Back problems
Other diseases musculoskeletal
Other endocrine system Thyroid disease
Gout
Other endocrine and immune diseases
Respiratory system Bronchitis/ Emphysema
Cough or sore throat
Other diseases of respiratory system
Common cold
Influenza
Eye & adnexa Other diseases of eye and adnexa
Visual disturbances
Ear & mastoid Otitis media
Ear pain
Other diseases ear & mastoid proc





Digestive system Diarrhoea enteritis
Constipation
Dental problems
Other diseases digestive system
Genito-urinary system Kidney diseases
Other diseases urinary system







Other diseases skin and subcutaneous
tissue
Psoriasis
Diseases of the blood Diseases of blood
Complications of childbirth Complications of pregnancy etc









Headache due to stress
Headache unspecified or trivial
Virus
Other symptoms and ill-defined conditions
C Drug usage tables
Table C1: No. of annual scripts per person, by drug type, 2003 (percent distribution)
No. of scripts Drug class
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
1 39.23 37.11 8.53 15.00 7.20 7.19 7.55 6.66 37.70 17.73 35.87 18.24 23.98 40.60 16.93 30.68 22.50 64.80 30.19
2 14.13 16.61 9.33 8.04 4.85 4.48 4.77 4.49 18.05 10.42 14.12 9.25 10.92 23.84 12.63 17.46 12.45 9.99 13.85
3 8.26 8.52 8.71 6.85 4.18 3.91 4.10 3.98 9.69 8.94 8.35 7.10 6.63 12.07 9.69 16.57 11.59 5.45 8.45
4 6.31 6.34 8.59 6.31 3.99 3.68 3.93 3.77 6.73 7.54 5.94 5.93 5.13 7.71 9.54 9.83 10.51 3.88 6.2830/06/2008 15:47 Annie Abello, Sharyn Lymer, Laurie Brown, Ann Harding and Ben Phil… in a Microsimulation Model of Pharmaceutical Drug Usage and Cost
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4 6.31 6.34 8.59 6.31 3.99 3.68 3.93 3.77 6.73 7.54 5.94 5.93 5.13 7.71 9.54 9.83 10.51 3.88 6.28
5 4.35 4.52 5.87 5.40 3.99 3.86 4.14 3.97 4.55 6.24 4.37 5.47 4.41 4.58 8.73 4.90 7.91 2.99 4.63
6 3.69 3.97 5.83 7.05 4.73 4.62 5.22 4.77 3.57 6.61 3.58 6.02 4.58 3.11 11.64 4.89 6.69 2.81 3.86
7 3.32 2.89 5.60 6.04 4.05 4.02 4.26 4.26 2.71 5.43 3.54 5.70 3.79 2.03 5.74 3.28 5.15 1.86 3.16
8 3.06 2.45 4.38 4.02 4.19 3.97 3.95 4.66 2.22 4.33 3.03 4.91 3.49 1.44 3.85 2.07 3.73 1.61 2.65
9 2.76 2.01 3.41 3.19 4.49 4.68 4.35 5.74 1.77 3.87 2.21 4.48 3.60 1.02 2.96 1.58 2.60 1.31 2.26
10 2.89 1.80 3.46 3.52 6.15 6.61 6.09 8.40 1.48 3.85 1.89 4.59 4.40 0.75 2.88 1.54 2.21 1.22 2.04
11 3.39 1.54 3.44 6.08 12.60 13.32 13.07 15.47 1.26 4.75 1.70 5.32 6.94 0.57 3.04 1.40 1.86 1.30 1.90
12 3.57 1.48 3.38 10.70 22.95 23.72 24.40 21.68 1.15 6.27 1.61 6.55 10.01 0.46 3.80 1.85 1.69 1.40 1.91
13 – 24 4.95 7.11 21.97 15.30 16.27 15.85 13.96 11.96 6.19 12.81 10.25 15.41 11.65 1.63 7.86 3.84 8.49 1.38 12.34
25 – 36 0.09 2.06 6.51 2.11 0.35 0.09 0.20 0.18 1.62 1.07 2.11 0.91 0.41 0.17 0.60 0.10 2.03 0.00 4.12
37 – 48 0.01 0.84 0.87 0.32 0.01 0.00 0.01 0.01 0.63 0.12 0.66 0.09 0.04 0.03 0.09 0.01 0.47 0.00 1.46
49+ 0.00 0.74 0.12 0.07 0.00 0.00 0.00 0.00 0.69 0.03 0.76 0.03 0.01 0.01 0.01 0.00 0.11 0.00 0.88











12 Mental: antidepressants 17 Anti-epileptics
3 Diabetes 8 Cholesterol & trig 13 Stomach medications 18 Direct acting
antivirals
4 Vasodilators 9 Analgesics 14 Antibiotics 19 All other
medications
5 ACE inhibitors 10 Mental:
antipsychotics
15 Cancer: antineoplastics
Table C2: Distribution of drug usage per specific health condition
Health group Health condition Drug class





48 . . 0 . 0 . 10 1 1 39 100
Osteoarthritis 63 . 0 1 0 0 0 19 1 1 14 100
Arthritis NEC 63 1 1 0 . 1 0 16 0 1 18 100
2 NHPA
Asthma





. . 97 0 0 . 1 . . . 0 1 100
Diabetes mellitus —
Type 2
. . 93 0 2 1 1 0 . . 0 3 100
Diabetes
unspecified
1 . 92 0 1 . 1 0 . . 1 3 100
4 NHPA
Heart circ
Atherosclerosis 5 . . 16 . 1 33 6 11 . . 2 26 100
Fluid problems NOS 1 . 0 1 . . 0 . . 98 100
Varicose veins 9 . . . 1 . . 14 . 4 . 72 100
Haemorrhoids . . . . . . . 4 . . . 96 100
Other dis circulatory
system
1 0 . 10 2 4 28 0 47 0 . . 8 100
Hypertension 0 0 0 20 27 0 25 0 2 0 0 0 25 100
Heart disease 0 0 0 34 9 0 22 1 7 0 0 0 26 100
Stroke 2 . . 10 2 13 18 1 31 . . . 23 100
Ill-def symp heart
cond
1 . 0 25 9 0 18 1 5 0 0 0 40 100





11 43 39 8 100
Other mental
disorders
9 5 74 11 100
Depression 12 9 69 10 100
Psychoses 60 11 15 14 100
Emotional problems
NEC






. . . . . 59 6 35 100
Mental ret delays
devt
. . . . . . 15 79 6 100
6 NHPA
Cancer
Skin cancer 7 92.5 100
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1 1 . 2 0 1 . 13 . 3 4 59 16 100
Fractures 18 1 . . . . . 53 . 5 0 17 5 100
Disloc sprains and
strains
50 . . . . 1 . 30 . 7 1 8 2 100
Internal injuries 11 . . . . . . 37 . 0 0 41 11 100
Open wounds 0 . . . . . . 12 . 0 0 70 19 100
Bruising and
crushing
23 . . . . . . 43 . . . 27 7 100
Entry of foreign
bodies
0 . . . . . . 5 . . . 75 20 100
Burns and scalds 0 . . . . . . 14 . . . 68 18 100
Poisoning other
than by food
0 . . . . . . 0 . . . 79 21 100
Other injuries 0 2 . . . 1 3 10 . 0 . 66 18 100
Injuries type not
stated
100 . . . . . . 0 . . . 0 0 100
8 Muscoskel
sys
Sciatica 46 . . . . . 38 . 8 0 8 100
Dis of the interver
disc
29 . . . . . 51 . 6 4 11 100
Back problems
(unspecified)
35 . . 0 . . 46 0 8 3 7 100
Other dis
musculoskel
32 . 1 1 . 19 0 4 3 40 100
Curvature of spine 32 . . . . 53 . 0 15 0 100
Osteoporosis 10 . . . . 6 . 1 0 83 100
Rheumatism 48 . . . 6 . 3 11 . 0 0 32 100
Absence of limbs or
parts
0 . . . . . . 19 . 0 0 81 100
Musculoskeletal
deformities
39 . . . . . . 30 . 3 0 28 100
9 Other
endocrine
Thyroid disease 100 100
Gout 15 0 . 0 0 0 . 2 . 0 . 82 100
Obesity . . . . . . 2 3 . . . 95 100
Oth endocrine and
imm
0 0 0 0 0 0 1 0 0 0 0 98 100
High blood sugar . . 91 . . . . . . . . 9 100





. 66 1 . 0 . 0 . 0 0 17 0 16 100
Sinusitis 0 52 . . . . . 3 0 . . 22 1 21 100
Cough or sore
throat
0 19 . . . . . 3 . . . 39 1 37 100
Other dis
respiratory system
0 24 . . 1 1 . 2 0 0 . 36 1 34 100
Common cold . 12 . . . . . 8 . . . 41 1 39 100
Hayfever . 49 . . . . . 1 . 0 0 25 1 24 100
Influenza . 8 . . . . . 4 . . . 45 1 42 100
11 Visual dist Blindness not corr
glasses
20 . . 1 . . . . . . 79 100
Other dis eye and
adnexa
. 2 . 3 0 . 2 . . . 60 1 33 100
Visual disturbances . . . 2 . . . . 13 . 85 100
Cataracts . . . 8 . . . . . . 92 100
Glaucoma . . . 27 1 . 0 . . . 72 100
Hypermetropia/Far-
sighted
. . . . . . . . . . 100 100
Myopia / Short-
sighted
. . . . . . . . . . 100 100
Presbyopia . . . . . . . . . . 100 100
12 Ear &
mastoid
Otitis media . 1 . . . . . 1 . 0 . 62 1 34 100
Deafness
(complete/ partial)
. . . . . 48 . . . . . 34 18 100
Ear pain 3 2 . . . . . 15 . . . 51 1 28 100
Oth dis ear &
mastoid proc
. 1 . 1 . 12 . 1 1 7 1 50 1 27 100
13 Nerv sys Epilepsy 0 . . 0 . . . . 0 5 1 93 100
Other dis nervous
system
16 . . . . . . 19 1 1 15 48 100
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Paralysis . . . . . . . 14 12 10 . 64 100
Oth hered dis nerv
sys
1 . . 1 1 2 . 7 . 7 5 76 100
14 Infectious
dis
Herpes . . . . . . . . . . 2 98 100
Tinea . . . . . . . . . . . 100 100
Other infectious dis 1 3 . . . . . 2 . . 2 92 100
15 Digestive
sys
Diarrhoea enteritis . . . . . . 1 2 . 0 0 75 2 19 100
Ulcer 0 0 . 0 . 0 . 0 . . 0 40 49 10 100
Hernia . . . 0 . 0 . 2 . . 1 96 100
Constipation . . . 1 3 . . . . . 1 77 19 100
Dental problems 2 2 . . . . . 24 . 1 . 72 100
Other dis digestive
system
1 . . 0 0 1 0 4 0 1 1 92 100
16 Genito-
urinary
Kidney diseases 1 0 . 3 2 1 1 3 . . 1 89 100
Other dis urinary
system
. . 1 0 1 0 . . . 1 7 76 4 10 100
Other dis genital
system
3 1 . 0 . 0 . 5 . 1 1 85 4 100
Disorders of
menstruation
6 . . 0 . . . 2 . 0 1 88 4 100
17 Skin
subcut tiss
Skin rash NOS . . . . . . . 0 . . . 100 100
Eczema dermatitis 0 1 . . . . . . 0 0 0 99 100
Acne . . . . . . . . . . . 100 100
Oth dis skin and
subcut tiss
0 . . . . 0 . 2 . 0 0 8 89 100
Psoriasis 0 1 . . . . 0 0 . 1 . 98 100
18 Dis of the
blood





. 13 . . . . . . . . . 69 18 100
20 Oth
symptoms
Allergy NEC 1 33 . . . . . 1 . 1 1 64 100
Insomnia 0 . . 0 . . . 3 1 75 16 4 100
Pyrexia 4 . . . . . . 21 . . . 25 25 25 100
Localised swelling 27 . . . . . . . . . . 73 100
Difficulty breathing . 51 . 2 11 15 5 1 . . 1 . 15 100
Chest pain 9 8 . 23 . 15 12 . 17 . . 2 15 100
Abdominal pain 7 . . 1 . 1 . 14 . . . 77 100
Heartburn 2 . . . . . . . . . . 98 100
Dizziness . . . . . 10 . 10 2 . 4 75 100
Headache due to
stress
. . . . . . . 48 . 23 . 28 100
Headache unspec or
trivial
4 0 . 1 . 0 . 86 0 0 2 5 100
Virus 1 4 . . 0 . . 12 . . . 83 100
Oth symp ill-
defined cond
2 3 . 3 0 0 1 9 1 5 5 71 100
21 Preventive Checkup/
examination
8 . 5 . 2 . . . . . 4 81 100
Contraceptive
management
. . . . 0 . . . . 1 . 99 100
Counselling . . . . . . . . . . . 100 100
Immunisation . . . . 8 . . . . . . 92 100
22 Congenital Congenital
anomalies
21 . . . 2 . . 10 . . . 67 100
23 Disability Speech impediment
NEC
. 29 . . . . . . . 71 . 0 100
Blackouts loss of
cons NEC
. . . . . . . . . 42 . 58 100
Missing organs NEC . 49 . . . . . . . . . 51 100
Due to rounding, totals do not always add up to 100. 
Source: NATSEM estimates using 1995 NHS.
Table C3: Distribution of persons by concession card status and age:
actual vs. model estimates (percent)
Medicare Australia
2003
Model 2003-04 % Difference
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All 100 100 100 100
0-4 1 5 2 6 0 0
5-9 2 5 2 6 0 0
10-
14
2 5 3 5 0 -1
15-
19
4 6 4 7 0 -1
20-
24
4 5 4 5 0 1
25-
29
6 4 6 4 0 0
30-
34
8 5 7 4 1 0
35-
39
8 5 9 5 0 0
40-
44
11 5 13 5 -2 0
45-
49
13 5 15 4 -2 1
50-
54
15 4 15 4 0 0
55-
59
14 5 11 6 4 0
60-
64
8 7 6 7 2 0
65-
69
2 9 2 10 1 -1
70-
74
1 9 1 9 0 0
75+ 1 16 1 14 0 2
Table C4: Average scripts per person by concession card status, gender and
age group: actual vs. model estimates
Medicare Australia
2003
Model 2003-04 % Difference
Gender Age
group
Concessional General Concessional General Concessional General
All 21.5 9.6 21.9 8.7 -2 10
Males 0-4 4.2 2.5 4.4 2.6 -5 -2
5-9 4.1 2.7 4.4 2.8 -7 -4
15-
24
5.1 3.8 5.4 3.4 -6 12
25-
39
10.1 5.6 10.0 4.9 1 13
40-
64
22.1 13.0 22.9 11.1 -3 17
65 + 35.6 26.2 35.4 18.6 1 41
Females 0-4 3.7 2.5 4.0 2.5 -8 -1
5-9 3.5 2.6 3.9 2.6 -10 -3
15-
24
5.8 3.6 5.7 3.3 2 7
25-
39
10.0 5.2 9.5 4.7 5 12
40-
64
24.6 10.8 24.0 10.1 3 6
65 + 41.7 19.5 41.7 19.8 0 -1
Table C5: Average no. of scripts by concession card status and drug




Concessional General Concessional General
Ave. no. scripts per person 21.5 9.6 21.9 8.7
No. of drugs classes per
person
3.4 1.9 3.5 1.7
Ave. no.
scripts/person/drug
6.3 5.2 6.3 5.2
1 Anti-inflammatories 4.6 3.1 4.6 3.1
2 Asthma medications 6.5 3.3 6.5 3.3
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4 Vasodilators 8.3 4.6 8.3 4.6
5 ACE inhibitors 9.5 8.2 9.5 8.2
6 Angiotensins 9.4 8.5 9.4 8.5
7 Calcium channel blockers 9.3 7.7 9.3 7.7
8 Cholesterol & trig.
reducers
9.4 8.0 9.4 8.0
9 Analgesics 5.0 5.3 5.0 5.2
10 Antipsychotics 6.9 5.8 6.9 5.7
11 Anxiolytics & hypnotics 6.1 3.1 6.1 3.1
12 Antidepressants 7.5 6.4 7.5 6.4
13 Stomach medications 7.0 5.2 7.0 5.2
14 Antibiotics 2.9 2.3 2.9 2.3
15 Cancer: antineoplastics 5.7 5.8 5.7 5.8
16 Genitourinary 3.9 2.7 3.9 2.7
17 Anti-epileptics 6.1 5.2 6.1 5.2
18 Direct acting antivirals 2.3 2.7 2.3 2.7
19 All other medications 7.8 4.4 7.8 4.4
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